Outlook Therapeutics faces a pivotal FDA decision for Lytenava on December 31st, following two prior rejections. Read why ...

Emotions are constructed, not discovered. Relational safety—not precise labels—allows the brain to tolerate uncertainty, ...

Flood of unreality is an endpoint of algorithm-driven internet and product of an economy dependent on a few top tech firms ...

No, Microsoft is not rewriting Windows in Rust. The clarification comes after a LinkedIn post by a Microsoft Distinguished ...

In a quarterly report filed with the U.S. Securities and Exchange Commission on November 14, 2025 ( SEC filing ), TREMBLANT CAPITAL GROUP disclosed a new position in CyberArk Software Ltd.

Agios upgraded after FDA approval of Aqvesme for thalassemia. Explore AGIO’s financial outlook, upside potential, and future ...

Ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) in the phase ...

Explore the top antivirus solutions for Windows in 2025, focusing on comprehensive security, compliance, and resilience for enterprises in the evolving threat landscape.

The KINECT-DCP trial evaluated the efficacy and safety of valbenazine in patients with dyskinesia due to cerebral palsy who experience choreiform movements.

Millions of people in the U.S. and around the world are living with hepatitis C virus (HCV). But over the past decade, direct-acting antivirals (DAA) have proven effective against HCV, curing more ...

It’s a sequence taken straight out of the Bible, a new spin on the story of Abraham feeling pressured to kill his son Isaac.

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings ...